Elliot Marseille - Group sessions can make psychedelic treatment more accessible: Empirical evidence

Group psychedelic therapy serves as an effective method to scale access and reduce clinician workload compared to individual treatment sessions. Empirical data shows that shifting to group settings allows for a more efficient allocation of professional personnel, effectively doubling the capacity to treat patients while maintaining safety. Clinician time is reduced by approximately 52 percent for MDMA-assisted PTSD therapy and 32 percent for psilocybin-assisted depression treatment. While the reduction in overall variable cost is more modest, the significant amplification of scarce, skilled clinician power represents a critical development in making these therapies widely available to the millions who could benefit.